Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06908252 · ClinicalTrials.gov registry record · Phase 4
MAPS PrEP Van Study
A Phase 4 study of HIV Infection, sponsored by Duke University.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT06908252 is a Phase 4 study of HIV Infection that is actively recruiting participants, run by Duke University. The registered enrollment target is 20 participants, below the 243-participant average among 73 other HIV Infection trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06908252, a Phase 4 study of HIV Infection, is actively recruiting participants, sponsored by Duke University.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
For this study the investigators aim to see if giving participants an oral HIV prevention medication on a medical van, is a good option of care for individuals who inject drugs and/or are sexually active and therefore at a higher risk of contracting HIV.
Conditions Studied
Interventions
- DRUG Pre-Exposure Prophylaxis (PrEP)
Study Locations (1)
North Carolina
- Duke Department of Population Health Sciences - Durham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2025-09-17 |
| Est. Completion | 2026-07-31 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06908252
The ClinicalTrials.gov registry entry for NCT06908252 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 243-participant average among 73 other HIV Infection trials with a reported enrollment target (92% lower). The listed sponsor is Duke University, which has 1,725 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with HIV Infection appearing as the primary indexed condition, and to 1 intervention - of which Pre-Exposure Prophylaxis (PrEP) is the first listed.
NCT06908252 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.
Frequently Asked Questions
What is clinical trial NCT06908252 about?
NCT06908252 is a clinical study titled "MAPS PrEP Van Study". For this study the investigators aim to see if giving participants an oral HIV prevention medication on a medical van, is a good option of care for individuals who inject drugs and/or are sexually active and therefore at a higher risk of contracting HIV.
What is the current status of trial NCT06908252?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 20 participants. The study started on 2025-09-17. Estimated completion is 2026-07-31.
What conditions does trial NCT06908252 study?
This clinical trial studies the following conditions: HIV Infection.
What interventions are being tested in trial NCT06908252?
The interventions under investigation include: Pre-Exposure Prophylaxis (PrEP) (DRUG).
Who is sponsoring clinical trial NCT06908252?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06908252 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV Infection
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Boosted Lexiva With Lovaza Adjunctive Therapy in Hypertriglyceridemic, HIV-Infected Subjects
COMPLETED · Phase 4
-
Improving Immunogenicity of Influenza Vaccine in HIV Infected Individuals
COMPLETED · Phase 4
-
A Multicenter Study to Assess the Tolerability of Once Daily Lopinavir/Ritonavir (LPV/r) Liquid Versus Capsules
COMPLETED · Phase 4
-
IMPAACT 1077HS: Examining Benefits of HAART Continuation in Postpartum Women
COMPLETED · Phase 4
-
Safety and Efficacy Study of Switching From Epzicom to Truvada
COMPLETED · Phase 4
-
A Trial to Determine the Long-term Durability of Virologic Suppression in Kaletra Recipients With Imperfect Adherence
COMPLETED · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.